has been refreshed! Take a tour.
  • Meningococcal ACWY
  • Vaccine Recommendations

Menveo (MenACWY-CRM) is approved by the FDA for use in children as young as 2 months of age. What is the ACIP recommendation for use of this vaccine?

Menveo, in the two-vial presentation that requires reconstitution, is approved for people age 2 months through 55 years. The one-vial formulation that does not require reconstitution was licensed in 2022 for ages 10 through 55 years and should not be used for children younger than age 10. For children beginning the vaccination series at age 2 months the schedule is 4 doses at age 2, 4, 6, and 12 to 15 months. Fewer doses are recommended for children beginning the vaccination series at age 7 months or older. See the document at for details.

ACIP recommends the use of Menveo in high-risk children 2 through 23 months of age: children with persistent complement deficiency, including those taking a complement inhibitor such as eculizumab (Soliris) or ravulizumab (Ultomiris), functional or anatomic asplenia, HIV infection, who travel to or reside in regions where meningitis is epidemic or hyperendemic, or who are at risk during a community outbreak attributable to a vaccine serogroup. Menactra (MenACWY-D) can be given to children 9 months and older at increased risk of meningococcal disease. MenQuadfi (MenACWY-TT) may be used for children at increased risk who are age 2 years and older. These recommendations are summarized in Table 3 of the recommendations published by ACIP in MMWR in 2020:

Last reviewed: July 15, 2023

This page was updated on .